Patents by Inventor Marie-Edith Meyre
Marie-Edith Meyre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000940Abstract: The invention concerns a particle and a composition comprising particles and their use in oncology. Specifically, the particles are porous, high-Z and carbon-free particles having internal pores, of longest dimension of at least 0.5 nm, and are for use in altering or destroying target cells in a mammal when said cells are exposed to ionizing radiation. The present invention also provides a porous, high-Z and carbon-free particle wherein at least part of the porous structure of the particle is occupied by at least one therapeutic agent which is preferably for use in oncology.Type: ApplicationFiled: November 30, 2021Publication date: January 4, 2024Inventors: LAURENT LEVY, CÉLINE BERJAUD, ALEXANDRA MADEIRA, JULIE MARILL, MARIE-EDITH MEYRE
-
Patent number: 11717684Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: GrantFiled: March 18, 2022Date of Patent: August 8, 2023Assignee: NANOBIOTIX S.A.Inventors: Marie-Edith Meyre, Agnès Pottier, Laurent Levy
-
Patent number: 11497717Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100.Type: GrantFiled: December 18, 2018Date of Patent: November 15, 2022Assignee: NANOBIOTIX S.A.Inventors: Marie-Edith Meyre, Laurent Levy, Agnès Pottier
-
Patent number: 11471482Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above (200), and an insulator material with a dielectric constant ?ijk equal to or below (100).Type: GrantFiled: December 18, 2018Date of Patent: October 18, 2022Assignee: NANOBIOTIX S.A.Inventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre
-
Patent number: 11471410Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: GrantFiled: August 26, 2019Date of Patent: October 18, 2022Assignee: CURADIGM SASInventors: Matthieu Germain, Marie-Edith Meyre, Agnès Pottier, Laurent Levy
-
Publication number: 20220212008Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: ApplicationFiled: March 18, 2022Publication date: July 7, 2022Inventors: MARIE-EDITH MEYRE, AGNÈS POTTIER, LAURENT LEVY
-
Patent number: 11357724Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.Type: GrantFiled: August 29, 2019Date of Patent: June 14, 2022Assignee: CURADIGM SASInventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre, Audrey Darmon, Matthieu Germain
-
Patent number: 11304902Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.Type: GrantFiled: November 24, 2015Date of Patent: April 19, 2022Assignee: CURADIGM SASInventors: Agnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
-
Patent number: 11278723Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: GrantFiled: December 19, 2017Date of Patent: March 22, 2022Assignee: NANOBIOTIX S.A.Inventors: Marie-Edith Meyre, Agnès Pottier, Laurent Levy
-
Patent number: 11247054Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: GrantFiled: December 19, 2017Date of Patent: February 15, 2022Assignee: NANOBIOTIX S.A.Inventors: Laurent Levy, Marie-Edith Meyre, Agnès Pottier
-
Patent number: 11229705Abstract: The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons.Type: GrantFiled: December 19, 2017Date of Patent: January 25, 2022Assignee: NANOBIOTIXInventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre
-
Patent number: 11191846Abstract: The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody.Type: GrantFiled: August 1, 2018Date of Patent: December 7, 2021Assignee: CURADIGM SASInventors: Marie-Edith Meyre, Agnes Pottier, Matthieu Germain, Celine Berjaud, Audrey Darmon
-
Patent number: 10945965Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.Type: GrantFiled: December 17, 2012Date of Patent: March 16, 2021Assignee: NANOBIOTIXInventors: Agnes Pottier, Laurent Levy, Marie-Edith Meyre
-
Publication number: 20210015756Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100.Type: ApplicationFiled: December 18, 2018Publication date: January 21, 2021Inventors: MARIE-EDITH MEYRE, LAURENT LEVY, AGNÈS POTTIER
-
Publication number: 20200405750Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above (200), and an insulator material with a dielectric constant ?ijk equal to or below (100).Type: ApplicationFiled: December 18, 2018Publication date: December 31, 2020Inventors: AGNÈS POTTIER, LAURENT LEVY, MARIE-EDITH MEYRE
-
Patent number: 10765632Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.Type: GrantFiled: November 24, 2015Date of Patent: September 8, 2020Assignee: CURADIGM SASInventors: Matthieu Germain, Marie-Edith Meyre, Agnes Pottier, Laurent Levy
-
Publication number: 20200086120Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: ApplicationFiled: December 19, 2017Publication date: March 19, 2020Inventors: LAURENT LEVY, MARIE-EDITH MEYRE, AGNÈS POTTIER
-
Publication number: 20200009050Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Inventors: AGNÈS POTTIER, LAURENT LEVY, MARIE-EDITH MEYRE, AUDREY DARMON, MATTHIEU GERMAIN
-
Publication number: 20190374465Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: ApplicationFiled: August 26, 2019Publication date: December 12, 2019Inventors: MATTHIEU GERMAIN, MARIE-EDITH MEYRE, AGNÈS POTTIER, LAURENT LEVY
-
Publication number: 20190351231Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.Type: ApplicationFiled: December 19, 2017Publication date: November 21, 2019Inventors: MARIE-EDITH MEYRE, AGNÈS POTTIER, LAURENT LEVY